HCW BIOLOGICS INC (HCWB)
US40423R1059 - Common Stock
Overall HCWB gets a fundamental rating of 1 out of 10. We evaluated HCWB against 588 industry peers in the Biotechnology industry. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative. HCWB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year HCWB has reported negative net income.
In the past year HCWB has reported a negative cash flow from operations.
In the past 5 years HCWB always reported negative net income.
In the past 5 years HCWB always reported negative operating cash flow.
1.2 Ratios
HCWB's Return On Assets of -87.64% is on the low side compared to the rest of the industry. HCWB is outperformed by 73.63% of its industry peers.
The Return On Equity of HCWB (-185.63%) is worse than 69.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.64% | ||
| ROE | -185.63% | ||
| ROIC | N/A |
ROA(3y)-47.84%
ROA(5y)-53.34%
ROE(3y)-83.53%
ROE(5y)-77.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 19.65%, HCWB is in the better half of the industry, outperforming 75.68% of the companies in the same industry.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCWB has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HCWB is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.24, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HCWB (-4.24) is worse than 61.13% of its industry peers.
HCWB has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
HCWB has a worse Debt to Equity ratio (0.47) than 72.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.24 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
HCWB has a Current Ratio of 0.73. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.73, HCWB is doing worse than 93.15% of the companies in the same industry.
A Quick Ratio of 0.73 indicates that HCWB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.73, HCWB is doing worse than 92.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.73 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for HCWB have decreased strongly by -66.67% in the last year.
The Revenue for HCWB has decreased by -57.78% in the past year. This is quite bad
Measured over the past years, HCWB shows a very negative growth in Revenue. The Revenue has been decreasing by -11.50% on average per year.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-100%
Revenue 1Y (TTM)-57.78%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Revenue growth Q2Q-1.19%
3.2 Future
HCWB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.73% yearly.
HCWB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 141.38% yearly.
EPS Next Y16.94%
EPS Next 2Y8.14%
EPS Next 3Y1.73%
EPS Next 5YN/A
Revenue Next Year-33.63%
Revenue Next 2Y-36.09%
Revenue Next 3Y-38.75%
Revenue Next 5Y141.38%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.14%
EPS Next 3Y1.73%
5. Dividend
5.1 Amount
HCWB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HCW BIOLOGICS INC
NASDAQ:HCWB (4/26/2024, 7:00:02 PM)
After market: 1.94 +0.54 (+38.58%)1.3999
-0.06 (-4.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap52.94M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.64% | ||
| ROE | -185.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.65% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.73 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y16.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-57.78%
Revenue growth 3Y-11.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y